nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0443	0.137	CbGbCtD
Ziprasidone—CYP3A7—Paclitaxel—ovarian cancer	0.0443	0.137	CbGbCtD
Ziprasidone—CYP3A5—Paclitaxel—ovarian cancer	0.0332	0.103	CbGbCtD
Ziprasidone—CYP3A7—Docetaxel—ovarian cancer	0.032	0.0989	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.032	0.0989	CbGbCtD
Ziprasidone—CYP2D6—Vinorelbine—ovarian cancer	0.029	0.0896	CbGbCtD
Ziprasidone—CYP3A4—Topotecan—ovarian cancer	0.0262	0.0808	CbGbCtD
Ziprasidone—CYP3A5—Docetaxel—ovarian cancer	0.024	0.0742	CbGbCtD
Ziprasidone—CYP3A4—Vinorelbine—ovarian cancer	0.0184	0.0569	CbGbCtD
Ziprasidone—CYP3A4—Paclitaxel—ovarian cancer	0.013	0.04	CbGbCtD
Ziprasidone—CHRM3—muscle of abdomen—ovarian cancer	0.0115	0.087	CbGeAlD
Ziprasidone—CYP2D6—Doxorubicin—ovarian cancer	0.011	0.0339	CbGbCtD
Ziprasidone—CYP3A4—Docetaxel—ovarian cancer	0.00936	0.0289	CbGbCtD
Ziprasidone—HTR7—vein—ovarian cancer	0.00841	0.0638	CbGeAlD
Ziprasidone—H1F0—oviduct—ovarian cancer	0.00838	0.0636	CbGeAlD
Ziprasidone—CYP3A4—Doxorubicin—ovarian cancer	0.00698	0.0216	CbGbCtD
Ziprasidone—HTR2A—vein—ovarian cancer	0.00524	0.0398	CbGeAlD
Ziprasidone—HTR1E—myometrium—ovarian cancer	0.00454	0.0344	CbGeAlD
Ziprasidone—H1F0—myometrium—ovarian cancer	0.00268	0.0204	CbGeAlD
Ziprasidone—H1F0—embryo—ovarian cancer	0.00258	0.0196	CbGeAlD
Ziprasidone—DRD4—testis—ovarian cancer	0.00247	0.0188	CbGeAlD
Ziprasidone—CHRM5—epithelium—ovarian cancer	0.00244	0.0185	CbGeAlD
Ziprasidone—HTR1E—female gonad—ovarian cancer	0.00241	0.0183	CbGeAlD
Ziprasidone—H1F0—uterine cervix—ovarian cancer	0.00209	0.0158	CbGeAlD
Ziprasidone—DRD5—female reproductive system—ovarian cancer	0.00202	0.0153	CbGeAlD
Ziprasidone—H1F0—decidua—ovarian cancer	0.00199	0.0151	CbGeAlD
Ziprasidone—H1F0—endometrium—ovarian cancer	0.00189	0.0143	CbGeAlD
Ziprasidone—CHRM4—testis—ovarian cancer	0.00187	0.0142	CbGeAlD
Ziprasidone—DRD5—female gonad—ovarian cancer	0.00184	0.014	CbGeAlD
Ziprasidone—H1F0—gonad—ovarian cancer	0.00175	0.0133	CbGeAlD
Ziprasidone—H1F0—uterus—ovarian cancer	0.00174	0.0132	CbGeAlD
Ziprasidone—H1F0—female reproductive system—ovarian cancer	0.00156	0.0119	CbGeAlD
Ziprasidone—KCNH2—myometrium—ovarian cancer	0.00154	0.0117	CbGeAlD
Ziprasidone—ADRA2C—myometrium—ovarian cancer	0.00152	0.0115	CbGeAlD
Ziprasidone—H1F0—bone marrow—ovarian cancer	0.00148	0.0112	CbGeAlD
Ziprasidone—H1F0—female gonad—ovarian cancer	0.00142	0.0108	CbGeAlD
Ziprasidone—H1F0—vagina—ovarian cancer	0.00141	0.0107	CbGeAlD
Ziprasidone—HTR7—epithelium—ovarian cancer	0.0013	0.00986	CbGeAlD
Ziprasidone—H1F0—testis—ovarian cancer	0.00126	0.00958	CbGeAlD
Ziprasidone—ADRA1A—epithelium—ovarian cancer	0.00125	0.00951	CbGeAlD
Ziprasidone—HTR1B—female reproductive system—ovarian cancer	0.00125	0.00949	CbGeAlD
Ziprasidone—HRH1—myometrium—ovarian cancer	0.00124	0.00938	CbGeAlD
Ziprasidone—ADRA2A—myometrium—ovarian cancer	0.00121	0.00921	CbGeAlD
Ziprasidone—HTR1D—female reproductive system—ovarian cancer	0.00121	0.00919	CbGeAlD
Ziprasidone—KCNH2—uterine cervix—ovarian cancer	0.0012	0.0091	CbGeAlD
Ziprasidone—HTR2C—female reproductive system—ovarian cancer	0.0012	0.0091	CbGeAlD
Ziprasidone—ADRA2C—uterine cervix—ovarian cancer	0.00118	0.00898	CbGeAlD
Ziprasidone—SLC6A4—female reproductive system—ovarian cancer	0.00114	0.00863	CbGeAlD
Ziprasidone—CHRM1—female reproductive system—ovarian cancer	0.00113	0.0086	CbGeAlD
Ziprasidone—ADRA2C—decidua—ovarian cancer	0.00113	0.00856	CbGeAlD
Ziprasidone—KCNH2—endometrium—ovarian cancer	0.00108	0.00823	CbGeAlD
Ziprasidone—HTR7—gonad—ovarian cancer	0.00108	0.0082	CbGeAlD
Ziprasidone—ADRA2C—endometrium—ovarian cancer	0.00107	0.00812	CbGeAlD
Ziprasidone—CHRM3—female reproductive system—ovarian cancer	0.00101	0.00769	CbGeAlD
Ziprasidone—KCNH2—uterus—ovarian cancer	0.001	0.00759	CbGeAlD
Ziprasidone—HTR2A—embryo—ovarian cancer	0.000992	0.00753	CbGeAlD
Ziprasidone—CYP3A5—uterine cervix—ovarian cancer	0.00099	0.00752	CbGeAlD
Ziprasidone—ADRA2C—uterus—ovarian cancer	0.000986	0.00749	CbGeAlD
Ziprasidone—HRH1—epithelium—ovarian cancer	0.000969	0.00736	CbGeAlD
Ziprasidone—HTR7—female reproductive system—ovarian cancer	0.000965	0.00732	CbGeAlD
Ziprasidone—HRH1—uterine cervix—ovarian cancer	0.000961	0.0073	CbGeAlD
Ziprasidone—ADRA2A—uterine cervix—ovarian cancer	0.000944	0.00717	CbGeAlD
Ziprasidone—CHRM3—female gonad—ovarian cancer	0.000922	0.007	CbGeAlD
Ziprasidone—HRH1—decidua—ovarian cancer	0.000916	0.00695	CbGeAlD
Ziprasidone—H1F0—lymph node—ovarian cancer	0.000914	0.00694	CbGeAlD
Ziprasidone—ADRA2A—decidua—ovarian cancer	0.0009	0.00683	CbGeAlD
Ziprasidone—KCNH2—female reproductive system—ovarian cancer	0.000899	0.00682	CbGeAlD
Ziprasidone—HRH1—endometrium—ovarian cancer	0.000869	0.0066	CbGeAlD
Ziprasidone—ADRA2A—endometrium—ovarian cancer	0.000854	0.00648	CbGeAlD
Ziprasidone—KCNH2—bone marrow—ovarian cancer	0.000848	0.00644	CbGeAlD
Ziprasidone—Clozapine—CYP1B1—ovarian cancer	0.000823	0.425	CrCbGaD
Ziprasidone—CHRM3—testis—ovarian cancer	0.000818	0.00621	CbGeAlD
Ziprasidone—KCNH2—female gonad—ovarian cancer	0.000818	0.00621	CbGeAlD
Ziprasidone—KCNH2—vagina—ovarian cancer	0.000813	0.00617	CbGeAlD
Ziprasidone—HTR2A—epithelium—ovarian cancer	0.00081	0.00615	CbGeAlD
Ziprasidone—ADRA2C—female gonad—ovarian cancer	0.000807	0.00612	CbGeAlD
Ziprasidone—ADRA2C—vagina—ovarian cancer	0.000802	0.00609	CbGeAlD
Ziprasidone—ADRA2A—gonad—ovarian cancer	0.000792	0.00601	CbGeAlD
Ziprasidone—ADRA2A—uterus—ovarian cancer	0.000787	0.00597	CbGeAlD
Ziprasidone—HTR7—testis—ovarian cancer	0.000778	0.00591	CbGeAlD
Ziprasidone—DRD2—testis—ovarian cancer	0.000736	0.00559	CbGeAlD
Ziprasidone—KCNH2—testis—ovarian cancer	0.000725	0.0055	CbGeAlD
Ziprasidone—HRH1—female reproductive system—ovarian cancer	0.00072	0.00547	CbGeAlD
Ziprasidone—ADRA2C—testis—ovarian cancer	0.000715	0.00543	CbGeAlD
Ziprasidone—ADRA2A—female reproductive system—ovarian cancer	0.000707	0.00537	CbGeAlD
Ziprasidone—CYP3A5—female gonad—ovarian cancer	0.000675	0.00513	CbGeAlD
Ziprasidone—HTR2A—gonad—ovarian cancer	0.000674	0.00511	CbGeAlD
Ziprasidone—CYP3A5—vagina—ovarian cancer	0.000671	0.00509	CbGeAlD
Ziprasidone—HRH1—female gonad—ovarian cancer	0.000655	0.00497	CbGeAlD
Ziprasidone—HRH1—vagina—ovarian cancer	0.000651	0.00494	CbGeAlD
Ziprasidone—ADRA2A—female gonad—ovarian cancer	0.000644	0.00489	CbGeAlD
Ziprasidone—ADRA2A—vagina—ovarian cancer	0.00064	0.00486	CbGeAlD
Ziprasidone—HTR2A—female reproductive system—ovarian cancer	0.000602	0.00457	CbGeAlD
Ziprasidone—HRH1—testis—ovarian cancer	0.000581	0.00441	CbGeAlD
Ziprasidone—ADRA2A—testis—ovarian cancer	0.000571	0.00433	CbGeAlD
Ziprasidone—CYP3A4—female reproductive system—ovarian cancer	0.000557	0.00423	CbGeAlD
Ziprasidone—CYP2D6—female reproductive system—ovarian cancer	0.000548	0.00416	CbGeAlD
Ziprasidone—HTR2A—vagina—ovarian cancer	0.000544	0.00413	CbGeAlD
Ziprasidone—KCNH2—lymph node—ovarian cancer	0.000526	0.00399	CbGeAlD
Ziprasidone—ADRA2C—lymph node—ovarian cancer	0.000519	0.00394	CbGeAlD
Ziprasidone—CYP2D6—female gonad—ovarian cancer	0.000499	0.00378	CbGeAlD
Ziprasidone—HTR2A—testis—ovarian cancer	0.000485	0.00368	CbGeAlD
Ziprasidone—CYP2D6—testis—ovarian cancer	0.000442	0.00336	CbGeAlD
Ziprasidone—Aripiprazole—ABCB1—ovarian cancer	0.000439	0.227	CrCbGaD
Ziprasidone—Trazodone—ABCB1—ovarian cancer	0.000437	0.226	CrCbGaD
Ziprasidone—HRH1—lymph node—ovarian cancer	0.000421	0.0032	CbGeAlD
Ziprasidone—ADRA2A—lymph node—ovarian cancer	0.000414	0.00314	CbGeAlD
Ziprasidone—Clozapine—ABCB1—ovarian cancer	0.000236	0.122	CrCbGaD
Ziprasidone—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000217	0.000477	CcSEcCtD
Ziprasidone—Weight increased—Epirubicin—ovarian cancer	0.000217	0.000475	CcSEcCtD
Ziprasidone—Loss of consciousness—Docetaxel—ovarian cancer	0.000216	0.000474	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000216	0.000473	CcSEcCtD
Ziprasidone—Weight decreased—Epirubicin—ovarian cancer	0.000215	0.000472	CcSEcCtD
Ziprasidone—Hyperglycaemia—Epirubicin—ovarian cancer	0.000215	0.000471	CcSEcCtD
Ziprasidone—Cough—Docetaxel—ovarian cancer	0.000215	0.000471	CcSEcCtD
Ziprasidone—Angina pectoris—Doxorubicin—ovarian cancer	0.000215	0.000471	CcSEcCtD
Ziprasidone—Insomnia—Paclitaxel—ovarian cancer	0.000214	0.00047	CcSEcCtD
Ziprasidone—Pneumonia—Epirubicin—ovarian cancer	0.000213	0.000468	CcSEcCtD
Ziprasidone—Paraesthesia—Paclitaxel—ovarian cancer	0.000213	0.000466	CcSEcCtD
Ziprasidone—Hypertension—Docetaxel—ovarian cancer	0.000212	0.000466	CcSEcCtD
Ziprasidone—Infestation NOS—Epirubicin—ovarian cancer	0.000212	0.000465	CcSEcCtD
Ziprasidone—Infestation—Epirubicin—ovarian cancer	0.000212	0.000465	CcSEcCtD
Ziprasidone—Dyspnoea—Paclitaxel—ovarian cancer	0.000211	0.000463	CcSEcCtD
Ziprasidone—Somnolence—Paclitaxel—ovarian cancer	0.00021	0.000462	CcSEcCtD
Ziprasidone—Arthralgia—Docetaxel—ovarian cancer	0.000209	0.000459	CcSEcCtD
Ziprasidone—Myalgia—Docetaxel—ovarian cancer	0.000209	0.000459	CcSEcCtD
Ziprasidone—Chest pain—Docetaxel—ovarian cancer	0.000209	0.000459	CcSEcCtD
Ziprasidone—Nausea—Vinorelbine—ovarian cancer	0.000209	0.000459	CcSEcCtD
Ziprasidone—Renal failure—Epirubicin—ovarian cancer	0.000209	0.000458	CcSEcCtD
Ziprasidone—Dyspepsia—Paclitaxel—ovarian cancer	0.000208	0.000457	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000208	0.000456	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000208	0.000456	CcSEcCtD
Ziprasidone—Jaundice—Epirubicin—ovarian cancer	0.000207	0.000454	CcSEcCtD
Ziprasidone—Conjunctivitis—Epirubicin—ovarian cancer	0.000206	0.000452	CcSEcCtD
Ziprasidone—Dysuria—Doxorubicin—ovarian cancer	0.000206	0.000452	CcSEcCtD
Ziprasidone—Decreased appetite—Paclitaxel—ovarian cancer	0.000206	0.000451	CcSEcCtD
Ziprasidone—Dry mouth—Docetaxel—ovarian cancer	0.000205	0.000449	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000205	0.000449	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000204	0.000448	CcSEcCtD
Ziprasidone—Fatigue—Paclitaxel—ovarian cancer	0.000204	0.000448	CcSEcCtD
Ziprasidone—Sweating—Epirubicin—ovarian cancer	0.000203	0.000446	CcSEcCtD
Ziprasidone—Constipation—Paclitaxel—ovarian cancer	0.000202	0.000444	CcSEcCtD
Ziprasidone—Haematuria—Epirubicin—ovarian cancer	0.000202	0.000444	CcSEcCtD
Ziprasidone—Confusional state—Docetaxel—ovarian cancer	0.000202	0.000444	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000201	0.000441	CcSEcCtD
Ziprasidone—Weight increased—Doxorubicin—ovarian cancer	0.0002	0.00044	CcSEcCtD
Ziprasidone—Epistaxis—Epirubicin—ovarian cancer	0.0002	0.000439	CcSEcCtD
Ziprasidone—Infection—Docetaxel—ovarian cancer	0.000199	0.000437	CcSEcCtD
Ziprasidone—Weight decreased—Doxorubicin—ovarian cancer	0.000199	0.000437	CcSEcCtD
Ziprasidone—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000199	0.000436	CcSEcCtD
Ziprasidone—Pneumonia—Doxorubicin—ovarian cancer	0.000197	0.000433	CcSEcCtD
Ziprasidone—Shock—Docetaxel—ovarian cancer	0.000197	0.000433	CcSEcCtD
Ziprasidone—Nervous system disorder—Docetaxel—ovarian cancer	0.000197	0.000432	CcSEcCtD
Ziprasidone—Thrombocytopenia—Docetaxel—ovarian cancer	0.000196	0.000431	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—ovarian cancer	0.000196	0.000431	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—ovarian cancer	0.000196	0.000431	CcSEcCtD
Ziprasidone—Tachycardia—Docetaxel—ovarian cancer	0.000196	0.00043	CcSEcCtD
Ziprasidone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000195	0.000428	CcSEcCtD
Ziprasidone—Skin disorder—Docetaxel—ovarian cancer	0.000195	0.000428	CcSEcCtD
Ziprasidone—Bradycardia—Epirubicin—ovarian cancer	0.000194	0.000425	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000194	0.000425	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—ovarian cancer	0.000193	0.000423	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000192	0.000422	CcSEcCtD
Ziprasidone—Haemoglobin—Epirubicin—ovarian cancer	0.000191	0.00042	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—ovarian cancer	0.000191	0.00042	CcSEcCtD
Ziprasidone—Anorexia—Docetaxel—ovarian cancer	0.000191	0.00042	CcSEcCtD
Ziprasidone—Rhinitis—Epirubicin—ovarian cancer	0.000191	0.000419	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—ovarian cancer	0.000191	0.000419	CcSEcCtD
Ziprasidone—Haemorrhage—Epirubicin—ovarian cancer	0.000191	0.000418	CcSEcCtD
Ziprasidone—Hepatitis—Epirubicin—ovarian cancer	0.000191	0.000418	CcSEcCtD
Ziprasidone—Hypoaesthesia—Epirubicin—ovarian cancer	0.00019	0.000416	CcSEcCtD
Ziprasidone—Pharyngitis—Epirubicin—ovarian cancer	0.000189	0.000415	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—ovarian cancer	0.000188	0.000413	CcSEcCtD
Ziprasidone—Urinary tract disorder—Epirubicin—ovarian cancer	0.000188	0.000413	CcSEcCtD
Ziprasidone—Urticaria—Paclitaxel—ovarian cancer	0.000188	0.000413	CcSEcCtD
Ziprasidone—Oedema peripheral—Epirubicin—ovarian cancer	0.000188	0.000412	CcSEcCtD
Ziprasidone—Hypotension—Docetaxel—ovarian cancer	0.000187	0.000411	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—ovarian cancer	0.000187	0.000411	CcSEcCtD
Ziprasidone—Connective tissue disorder—Epirubicin—ovarian cancer	0.000187	0.000411	CcSEcCtD
Ziprasidone—Abdominal pain—Paclitaxel—ovarian cancer	0.000187	0.00041	CcSEcCtD
Ziprasidone—Body temperature increased—Paclitaxel—ovarian cancer	0.000187	0.00041	CcSEcCtD
Ziprasidone—Urethral disorder—Epirubicin—ovarian cancer	0.000187	0.00041	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—ovarian cancer	0.000185	0.000406	CcSEcCtD
Ziprasidone—Visual impairment—Epirubicin—ovarian cancer	0.000184	0.000403	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000183	0.000401	CcSEcCtD
Ziprasidone—Insomnia—Docetaxel—ovarian cancer	0.000181	0.000398	CcSEcCtD
Ziprasidone—Paraesthesia—Docetaxel—ovarian cancer	0.00018	0.000395	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—ovarian cancer	0.000179	0.000394	CcSEcCtD
Ziprasidone—Dyspnoea—Docetaxel—ovarian cancer	0.000179	0.000392	CcSEcCtD
Ziprasidone—Somnolence—Docetaxel—ovarian cancer	0.000178	0.000391	CcSEcCtD
Ziprasidone—Eye disorder—Epirubicin—ovarian cancer	0.000178	0.00039	CcSEcCtD
Ziprasidone—Tinnitus—Epirubicin—ovarian cancer	0.000178	0.00039	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—ovarian cancer	0.000177	0.000389	CcSEcCtD
Ziprasidone—Cardiac disorder—Epirubicin—ovarian cancer	0.000177	0.000388	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—ovarian cancer	0.000177	0.000388	CcSEcCtD
Ziprasidone—Dyspepsia—Docetaxel—ovarian cancer	0.000177	0.000387	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—ovarian cancer	0.000176	0.000387	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—ovarian cancer	0.000176	0.000387	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000175	0.000385	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—ovarian cancer	0.000175	0.000384	CcSEcCtD
Ziprasidone—Decreased appetite—Docetaxel—ovarian cancer	0.000174	0.000383	CcSEcCtD
Ziprasidone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000174	0.000383	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000174	0.000382	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—ovarian cancer	0.000174	0.000381	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000173	0.00038	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000173	0.00038	CcSEcCtD
Ziprasidone—Fatigue—Docetaxel—ovarian cancer	0.000173	0.000379	CcSEcCtD
Ziprasidone—Angiopathy—Epirubicin—ovarian cancer	0.000173	0.000379	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—ovarian cancer	0.000173	0.000379	CcSEcCtD
Ziprasidone—Immune system disorder—Epirubicin—ovarian cancer	0.000172	0.000377	CcSEcCtD
Ziprasidone—Mediastinal disorder—Epirubicin—ovarian cancer	0.000172	0.000377	CcSEcCtD
Ziprasidone—Constipation—Docetaxel—ovarian cancer	0.000172	0.000376	CcSEcCtD
Ziprasidone—Chills—Epirubicin—ovarian cancer	0.000171	0.000375	CcSEcCtD
Ziprasidone—Arrhythmia—Epirubicin—ovarian cancer	0.00017	0.000373	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—ovarian cancer	0.00017	0.000373	CcSEcCtD
Ziprasidone—Asthenia—Paclitaxel—ovarian cancer	0.00017	0.000373	CcSEcCtD
Ziprasidone—Alopecia—Epirubicin—ovarian cancer	0.000168	0.000369	CcSEcCtD
Ziprasidone—Mental disorder—Epirubicin—ovarian cancer	0.000167	0.000366	CcSEcCtD
Ziprasidone—Erythema—Epirubicin—ovarian cancer	0.000166	0.000364	CcSEcCtD
Ziprasidone—Malnutrition—Epirubicin—ovarian cancer	0.000166	0.000364	CcSEcCtD
Ziprasidone—Feeling abnormal—Docetaxel—ovarian cancer	0.000165	0.000363	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—ovarian cancer	0.000165	0.000361	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—ovarian cancer	0.000164	0.00036	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000164	0.00036	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—ovarian cancer	0.000164	0.000359	CcSEcCtD
Ziprasidone—Flatulence—Epirubicin—ovarian cancer	0.000163	0.000358	CcSEcCtD
Ziprasidone—Diarrhoea—Paclitaxel—ovarian cancer	0.000162	0.000355	CcSEcCtD
Ziprasidone—Back pain—Epirubicin—ovarian cancer	0.00016	0.000352	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—ovarian cancer	0.00016	0.000351	CcSEcCtD
Ziprasidone—Muscle spasms—Epirubicin—ovarian cancer	0.000159	0.00035	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—ovarian cancer	0.000159	0.000349	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000159	0.000348	CcSEcCtD
Ziprasidone—Body temperature increased—Docetaxel—ovarian cancer	0.000159	0.000348	CcSEcCtD
Ziprasidone—Abdominal pain—Docetaxel—ovarian cancer	0.000159	0.000348	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—ovarian cancer	0.000158	0.000347	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—ovarian cancer	0.000157	0.000345	CcSEcCtD
Ziprasidone—Dizziness—Paclitaxel—ovarian cancer	0.000157	0.000343	CcSEcCtD
Ziprasidone—Vision blurred—Epirubicin—ovarian cancer	0.000156	0.000343	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—ovarian cancer	0.000156	0.000342	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—ovarian cancer	0.000154	0.000339	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—ovarian cancer	0.000153	0.000337	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—ovarian cancer	0.000153	0.000337	CcSEcCtD
Ziprasidone—Anaemia—Epirubicin—ovarian cancer	0.000153	0.000336	CcSEcCtD
Ziprasidone—Agitation—Epirubicin—ovarian cancer	0.000152	0.000334	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—ovarian cancer	0.000151	0.000332	CcSEcCtD
Ziprasidone—Vomiting—Paclitaxel—ovarian cancer	0.000151	0.00033	CcSEcCtD
Ziprasidone—Rash—Paclitaxel—ovarian cancer	0.000149	0.000327	CcSEcCtD
Ziprasidone—Dermatitis—Paclitaxel—ovarian cancer	0.000149	0.000327	CcSEcCtD
Ziprasidone—Vertigo—Epirubicin—ovarian cancer	0.000149	0.000327	CcSEcCtD
Ziprasidone—Syncope—Epirubicin—ovarian cancer	0.000149	0.000326	CcSEcCtD
Ziprasidone—Leukopenia—Epirubicin—ovarian cancer	0.000148	0.000326	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—ovarian cancer	0.000148	0.000326	CcSEcCtD
Ziprasidone—Headache—Paclitaxel—ovarian cancer	0.000148	0.000325	CcSEcCtD
Ziprasidone—Hypersensitivity—Docetaxel—ovarian cancer	0.000148	0.000324	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—ovarian cancer	0.000148	0.000324	CcSEcCtD
Ziprasidone—Palpitations—Epirubicin—ovarian cancer	0.000147	0.000321	CcSEcCtD
Ziprasidone—Loss of consciousness—Epirubicin—ovarian cancer	0.000146	0.00032	CcSEcCtD
Ziprasidone—Cough—Epirubicin—ovarian cancer	0.000145	0.000317	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—ovarian cancer	0.000145	0.000317	CcSEcCtD
Ziprasidone—Asthenia—Docetaxel—ovarian cancer	0.000144	0.000316	CcSEcCtD
Ziprasidone—Hypertension—Epirubicin—ovarian cancer	0.000143	0.000314	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—ovarian cancer	0.000142	0.000311	CcSEcCtD
Ziprasidone—Arthralgia—Epirubicin—ovarian cancer	0.000141	0.00031	CcSEcCtD
Ziprasidone—Chest pain—Epirubicin—ovarian cancer	0.000141	0.00031	CcSEcCtD
Ziprasidone—Myalgia—Epirubicin—ovarian cancer	0.000141	0.00031	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—ovarian cancer	0.000141	0.000309	CcSEcCtD
Ziprasidone—Anxiety—Epirubicin—ovarian cancer	0.000141	0.000309	CcSEcCtD
Ziprasidone—Nausea—Paclitaxel—ovarian cancer	0.000141	0.000308	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00014	0.000308	CcSEcCtD
Ziprasidone—Dry mouth—Epirubicin—ovarian cancer	0.000138	0.000303	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—ovarian cancer	0.000138	0.000302	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—ovarian cancer	0.000138	0.000302	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—ovarian cancer	0.000137	0.000301	CcSEcCtD
Ziprasidone—Diarrhoea—Docetaxel—ovarian cancer	0.000137	0.000301	CcSEcCtD
Ziprasidone—Confusional state—Epirubicin—ovarian cancer	0.000136	0.000299	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—ovarian cancer	0.000136	0.000297	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000135	0.000296	CcSEcCtD
Ziprasidone—Infection—Epirubicin—ovarian cancer	0.000134	0.000295	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—ovarian cancer	0.000134	0.000294	CcSEcCtD
Ziprasidone—Shock—Epirubicin—ovarian cancer	0.000133	0.000292	CcSEcCtD
Ziprasidone—Nervous system disorder—Epirubicin—ovarian cancer	0.000133	0.000291	CcSEcCtD
Ziprasidone—Dizziness—Docetaxel—ovarian cancer	0.000133	0.000291	CcSEcCtD
Ziprasidone—Thrombocytopenia—Epirubicin—ovarian cancer	0.000133	0.000291	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—ovarian cancer	0.000132	0.000291	CcSEcCtD
Ziprasidone—Tachycardia—Epirubicin—ovarian cancer	0.000132	0.00029	CcSEcCtD
Ziprasidone—Skin disorder—Epirubicin—ovarian cancer	0.000131	0.000288	CcSEcCtD
Ziprasidone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000131	0.000287	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—ovarian cancer	0.000131	0.000287	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—ovarian cancer	0.000131	0.000287	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—ovarian cancer	0.000131	0.000287	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—ovarian cancer	0.00013	0.000286	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00013	0.000285	CcSEcCtD
Ziprasidone—Anorexia—Epirubicin—ovarian cancer	0.000129	0.000283	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—ovarian cancer	0.000128	0.00028	CcSEcCtD
Ziprasidone—Vomiting—Docetaxel—ovarian cancer	0.000128	0.00028	CcSEcCtD
Ziprasidone—Rash—Docetaxel—ovarian cancer	0.000127	0.000278	CcSEcCtD
Ziprasidone—Hypotension—Epirubicin—ovarian cancer	0.000126	0.000277	CcSEcCtD
Ziprasidone—Dermatitis—Docetaxel—ovarian cancer	0.000126	0.000277	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—ovarian cancer	0.000126	0.000277	CcSEcCtD
Ziprasidone—Headache—Docetaxel—ovarian cancer	0.000126	0.000276	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—ovarian cancer	0.000124	0.000273	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000123	0.00027	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—ovarian cancer	0.000123	0.00027	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—ovarian cancer	0.000123	0.000269	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000123	0.000269	CcSEcCtD
Ziprasidone—Insomnia—Epirubicin—ovarian cancer	0.000122	0.000269	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—ovarian cancer	0.000122	0.000268	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—ovarian cancer	0.000122	0.000267	CcSEcCtD
Ziprasidone—Paraesthesia—Epirubicin—ovarian cancer	0.000122	0.000267	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000121	0.000266	CcSEcCtD
Ziprasidone—Dyspnoea—Epirubicin—ovarian cancer	0.000121	0.000265	CcSEcCtD
Ziprasidone—Somnolence—Epirubicin—ovarian cancer	0.00012	0.000264	CcSEcCtD
Ziprasidone—Anorexia—Doxorubicin—ovarian cancer	0.000119	0.000262	CcSEcCtD
Ziprasidone—Nausea—Docetaxel—ovarian cancer	0.000119	0.000261	CcSEcCtD
Ziprasidone—Dyspepsia—Epirubicin—ovarian cancer	0.000119	0.000261	CcSEcCtD
Ziprasidone—Decreased appetite—Epirubicin—ovarian cancer	0.000118	0.000258	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—ovarian cancer	0.000117	0.000257	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000117	0.000256	CcSEcCtD
Ziprasidone—Fatigue—Epirubicin—ovarian cancer	0.000117	0.000256	CcSEcCtD
Ziprasidone—Constipation—Epirubicin—ovarian cancer	0.000116	0.000254	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000114	0.00025	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—ovarian cancer	0.000113	0.000248	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—ovarian cancer	0.000112	0.000247	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—ovarian cancer	0.000112	0.000245	CcSEcCtD
Ziprasidone—Feeling abnormal—Epirubicin—ovarian cancer	0.000112	0.000245	CcSEcCtD
Ziprasidone—Somnolence—Doxorubicin—ovarian cancer	0.000111	0.000244	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000111	0.000243	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—ovarian cancer	0.00011	0.000242	CcSEcCtD
Ziprasidone—Decreased appetite—Doxorubicin—ovarian cancer	0.000109	0.000239	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000108	0.000237	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—ovarian cancer	0.000108	0.000237	CcSEcCtD
Ziprasidone—Urticaria—Epirubicin—ovarian cancer	0.000108	0.000236	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—ovarian cancer	0.000107	0.000235	CcSEcCtD
Ziprasidone—Abdominal pain—Epirubicin—ovarian cancer	0.000107	0.000235	CcSEcCtD
Ziprasidone—Body temperature increased—Epirubicin—ovarian cancer	0.000107	0.000235	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—ovarian cancer	0.000103	0.000226	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000102	0.000225	CcSEcCtD
Ziprasidone—Hypersensitivity—Epirubicin—ovarian cancer	9.97e-05	0.000219	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—ovarian cancer	9.95e-05	0.000218	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—ovarian cancer	9.9e-05	0.000217	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—ovarian cancer	9.9e-05	0.000217	CcSEcCtD
Ziprasidone—Asthenia—Epirubicin—ovarian cancer	9.71e-05	0.000213	CcSEcCtD
Ziprasidone—Diarrhoea—Epirubicin—ovarian cancer	9.26e-05	0.000203	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—ovarian cancer	9.23e-05	0.000202	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—ovarian cancer	8.98e-05	0.000197	CcSEcCtD
Ziprasidone—Dizziness—Epirubicin—ovarian cancer	8.95e-05	0.000196	CcSEcCtD
Ziprasidone—Vomiting—Epirubicin—ovarian cancer	8.61e-05	0.000189	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—ovarian cancer	8.57e-05	0.000188	CcSEcCtD
Ziprasidone—Rash—Epirubicin—ovarian cancer	8.53e-05	0.000187	CcSEcCtD
Ziprasidone—Dermatitis—Epirubicin—ovarian cancer	8.53e-05	0.000187	CcSEcCtD
Ziprasidone—Headache—Epirubicin—ovarian cancer	8.48e-05	0.000186	CcSEcCtD
Ziprasidone—Dizziness—Doxorubicin—ovarian cancer	8.28e-05	0.000182	CcSEcCtD
Ziprasidone—Nausea—Epirubicin—ovarian cancer	8.04e-05	0.000176	CcSEcCtD
Ziprasidone—Vomiting—Doxorubicin—ovarian cancer	7.96e-05	0.000175	CcSEcCtD
Ziprasidone—Rash—Doxorubicin—ovarian cancer	7.9e-05	0.000173	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—ovarian cancer	7.89e-05	0.000173	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—ovarian cancer	7.85e-05	0.000172	CcSEcCtD
Ziprasidone—Nausea—Doxorubicin—ovarian cancer	7.44e-05	0.000163	CcSEcCtD
Ziprasidone—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	5.65e-06	6.51e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—ovarian cancer	5.64e-06	6.5e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	5.63e-06	6.49e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—ovarian cancer	5.62e-06	6.48e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PTEN—ovarian cancer	5.62e-06	6.48e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	5.62e-06	6.47e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PTEN—ovarian cancer	5.61e-06	6.47e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—ovarian cancer	5.6e-06	6.46e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTEN—ovarian cancer	5.6e-06	6.46e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—PIK3CA—ovarian cancer	5.6e-06	6.46e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MYC—ovarian cancer	5.6e-06	6.46e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CAV1—ovarian cancer	5.6e-06	6.45e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	5.6e-06	6.45e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PTEN—ovarian cancer	5.59e-06	6.44e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—HRAS—ovarian cancer	5.57e-06	6.43e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—AKT1—ovarian cancer	5.57e-06	6.42e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PTEN—ovarian cancer	5.57e-06	6.42e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	5.56e-06	6.41e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	5.55e-06	6.4e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—ovarian cancer	5.55e-06	6.4e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	5.54e-06	6.39e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	5.53e-06	6.38e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	5.53e-06	6.38e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	5.53e-06	6.37e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTEN—ovarian cancer	5.52e-06	6.36e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	5.5e-06	6.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	5.49e-06	6.33e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—ovarian cancer	5.49e-06	6.33e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HRAS—ovarian cancer	5.48e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—ovarian cancer	5.48e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	5.48e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	5.48e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	5.48e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AKT1—ovarian cancer	5.47e-06	6.31e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PIK3CA—ovarian cancer	5.47e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.46e-06	6.29e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	5.45e-06	6.29e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—ovarian cancer	5.45e-06	6.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	5.44e-06	6.27e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AKT1—ovarian cancer	5.44e-06	6.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—ovarian cancer	5.43e-06	6.26e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—ovarian cancer	5.42e-06	6.25e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HRAS—ovarian cancer	5.41e-06	6.24e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	5.41e-06	6.23e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MYC—ovarian cancer	5.41e-06	6.23e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	5.38e-06	6.21e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	5.38e-06	6.2e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MYC—ovarian cancer	5.38e-06	6.2e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	5.37e-06	6.19e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—TYMS—ovarian cancer	5.36e-06	6.18e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.35e-06	6.16e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	5.34e-06	6.15e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—ovarian cancer	5.33e-06	6.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PIK3CA—ovarian cancer	5.31e-06	6.12e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	5.3e-06	6.11e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	5.29e-06	6.1e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.29e-06	6.1e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	5.29e-06	6.1e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—ovarian cancer	5.29e-06	6.1e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	5.27e-06	6.07e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	5.26e-06	6.07e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—ovarian cancer	5.26e-06	6.06e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—ovarian cancer	5.25e-06	6.05e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	5.25e-06	6.05e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MYC—ovarian cancer	5.23e-06	6.03e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HRAS—ovarian cancer	5.18e-06	5.97e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—ovarian cancer	5.18e-06	5.97e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	5.17e-06	5.97e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—ovarian cancer	5.16e-06	5.95e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—ovarian cancer	5.16e-06	5.95e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MYC—ovarian cancer	5.15e-06	5.94e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	5.14e-06	5.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	5.12e-06	5.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	5.12e-06	5.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	5.11e-06	5.89e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STAT3—ovarian cancer	5.11e-06	5.89e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CG—ovarian cancer	5.1e-06	5.88e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NRAS—ovarian cancer	5.1e-06	5.87e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—ovarian cancer	5.09e-06	5.87e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	5.08e-06	5.85e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—ovarian cancer	5.06e-06	5.84e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AKT1—ovarian cancer	5.06e-06	5.84e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AKT1—ovarian cancer	5.06e-06	5.83e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	5.05e-06	5.82e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	5.04e-06	5.81e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	5.04e-06	5.81e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—ovarian cancer	5.03e-06	5.8e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AKT1—ovarian cancer	5.03e-06	5.79e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STAT3—ovarian cancer	5.03e-06	5.79e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STAT3—ovarian cancer	5.01e-06	5.78e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NRAS—ovarian cancer	5.01e-06	5.78e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NRAS—ovarian cancer	5e-06	5.77e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STAT3—ovarian cancer	5e-06	5.76e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—ovarian cancer	4.99e-06	5.76e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	4.99e-06	5.75e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NRAS—ovarian cancer	4.99e-06	5.75e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	4.98e-06	5.75e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STAT3—ovarian cancer	4.98e-06	5.75e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NRAS—ovarian cancer	4.97e-06	5.73e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	4.97e-06	5.73e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—ovarian cancer	4.97e-06	5.73e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—ovarian cancer	4.96e-06	5.72e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HRAS—ovarian cancer	4.94e-06	5.69e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STAT3—ovarian cancer	4.93e-06	5.69e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NRAS—ovarian cancer	4.92e-06	5.68e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	4.92e-06	5.67e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AKT1—ovarian cancer	4.92e-06	5.67e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	4.91e-06	5.66e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK3—ovarian cancer	4.88e-06	5.63e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HRAS—ovarian cancer	4.87e-06	5.62e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AKT1—ovarian cancer	4.84e-06	5.58e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	4.83e-06	5.57e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	4.8e-06	5.54e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK3—ovarian cancer	4.79e-06	5.52e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AKT1—ovarian cancer	4.78e-06	5.51e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	4.78e-06	5.51e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK3—ovarian cancer	4.76e-06	5.49e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	4.76e-06	5.48e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	4.75e-06	5.48e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MYC—ovarian cancer	4.75e-06	5.47e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—ovarian cancer	4.73e-06	5.45e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	4.71e-06	5.44e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	4.7e-06	5.42e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PIK3CA—ovarian cancer	4.7e-06	5.42e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MYC—ovarian cancer	4.67e-06	5.38e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—ovarian cancer	4.66e-06	5.38e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MYC—ovarian cancer	4.66e-06	5.37e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MYC—ovarian cancer	4.64e-06	5.36e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK1—ovarian cancer	4.64e-06	5.35e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—ovarian cancer	4.64e-06	5.35e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MYC—ovarian cancer	4.63e-06	5.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	4.62e-06	5.32e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.61e-06	5.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—ovarian cancer	4.6e-06	5.3e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	4.59e-06	5.29e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MYC—ovarian cancer	4.59e-06	5.29e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AKT1—ovarian cancer	4.57e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MYC—ovarian cancer	4.57e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	4.57e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	4.57e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—ovarian cancer	4.57e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	4.57e-06	5.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	4.56e-06	5.26e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK1—ovarian cancer	4.56e-06	5.26e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—ovarian cancer	4.56e-06	5.26e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	4.54e-06	5.24e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—ovarian cancer	4.54e-06	5.24e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK1—ovarian cancer	4.53e-06	5.22e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—ovarian cancer	4.53e-06	5.22e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	4.49e-06	5.17e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—ovarian cancer	4.48e-06	5.17e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CD—ovarian cancer	4.48e-06	5.17e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	4.47e-06	5.16e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	4.47e-06	5.16e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AKT1—ovarian cancer	4.47e-06	5.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	4.44e-06	5.12e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—ovarian cancer	4.44e-06	5.12e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—ovarian cancer	4.42e-06	5.09e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	4.4e-06	5.07e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—ovarian cancer	4.39e-06	5.06e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	4.37e-06	5.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	4.37e-06	5.04e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AKT1—ovarian cancer	4.36e-06	5.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AKT1—ovarian cancer	4.34e-06	5e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CAV1—ovarian cancer	4.32e-06	4.98e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—ovarian cancer	4.31e-06	4.98e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PIK3CA—ovarian cancer	4.31e-06	4.97e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—ovarian cancer	4.31e-06	4.96e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AKT1—ovarian cancer	4.3e-06	4.96e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—ovarian cancer	4.3e-06	4.95e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—ovarian cancer	4.29e-06	4.95e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—ovarian cancer	4.28e-06	4.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MYC—ovarian cancer	4.25e-06	4.9e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HRAS—ovarian cancer	4.25e-06	4.9e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—ovarian cancer	4.24e-06	4.88e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—ovarian cancer	4.23e-06	4.87e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	4.23e-06	4.87e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRAS—ovarian cancer	4.22e-06	4.87e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—ovarian cancer	4.21e-06	4.85e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	4.16e-06	4.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	4.16e-06	4.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	4.11e-06	4.74e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—ovarian cancer	4.06e-06	4.69e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	4.04e-06	4.66e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—ovarian cancer	4.04e-06	4.66e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	4.03e-06	4.65e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTEN—ovarian cancer	3.98e-06	4.59e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	3.96e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	3.96e-06	4.56e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PIK3CA—ovarian cancer	3.95e-06	4.56e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	3.94e-06	4.55e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.93e-06	4.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—ovarian cancer	3.93e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PIK3CA—ovarian cancer	3.93e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	3.93e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CB—ovarian cancer	3.91e-06	4.5e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—ovarian cancer	3.9e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	3.89e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	3.88e-06	4.48e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	3.88e-06	4.48e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—ovarian cancer	3.87e-06	4.46e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AKT1—ovarian cancer	3.84e-06	4.43e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—ovarian cancer	3.84e-06	4.42e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—ovarian cancer	3.83e-06	4.41e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—ovarian cancer	3.81e-06	4.4e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—ovarian cancer	3.8e-06	4.38e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—ovarian cancer	3.77e-06	4.34e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—ovarian cancer	3.76e-06	4.33e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AKT1—ovarian cancer	3.75e-06	4.32e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AKT1—ovarian cancer	3.73e-06	4.3e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRAS—ovarian cancer	3.73e-06	4.3e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRAS—ovarian cancer	3.67e-06	4.23e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRAS—ovarian cancer	3.66e-06	4.22e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRAS—ovarian cancer	3.65e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRAS—ovarian cancer	3.64e-06	4.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	3.63e-06	4.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	3.61e-06	4.16e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRAS—ovarian cancer	3.6e-06	4.15e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	3.59e-06	4.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	3.57e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—ovarian cancer	3.57e-06	4.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AKT1—ovarian cancer	3.52e-06	4.06e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—ovarian cancer	3.51e-06	4.05e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—ovarian cancer	3.5e-06	4.04e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—ovarian cancer	3.49e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—ovarian cancer	3.49e-06	4.02e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—ovarian cancer	3.48e-06	4.01e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.46e-06	3.99e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—ovarian cancer	3.45e-06	3.97e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—ovarian cancer	3.44e-06	3.96e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTEN—ovarian cancer	3.38e-06	3.89e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	3.34e-06	3.85e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AKT1—ovarian cancer	3.29e-06	3.79e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AKT1—ovarian cancer	3.24e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AKT1—ovarian cancer	3.23e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AKT1—ovarian cancer	3.23e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AKT1—ovarian cancer	3.22e-06	3.71e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AKT1—ovarian cancer	3.21e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—ovarian cancer	3.19e-06	3.68e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AKT1—ovarian cancer	3.18e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	3.17e-06	3.66e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.01e-06	3.48e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.95e-06	3.4e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.81e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTEN—ovarian cancer	2.6e-06	3e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.38e-06	2.75e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AKT1—ovarian cancer	2.3e-06	2.65e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AKT1—ovarian cancer	1.95e-06	2.24e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.84e-06	2.12e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AKT1—ovarian cancer	1.5e-06	1.73e-05	CbGpPWpGaD
